Oncolys BioPharma Inc. announced that it has entered into to enter into a purchase agreement with new investor EVO FUND for the stock acquisition rights and a private placement to issue 40,000 Series 20 stock acquisition rights at an issue price of ¥55 per right for the gross proceeds of ¥2,200,000 on June 14, 2024. The transaction has been approved by shareholders and is expected to close on July 1, 2024. The minimum exercise price will initially be ¥698.

The period will be from July 2, 2024 (inclusive) to March 3, 2025 (inclusive). Total amount to be paid is ¥2,794,200,000, Total amount to be paid for the Stock Acquisition Rights ¥2,200,000, Value of assets to be contributed upon exercise of the stock acquisition rights ¥2,792,000,000, Estimated issuance costs ¥8,000,000 and Estimated net proceeds ¥2,786,200,000.